In fact, the biased diagnostic performance of the BCR-ABL1 molecular detection and quantification may impact the inclusion of CML patients in therapy-stopping trials [49,50], which is currently one of the pivotal goals of CML management [4,51]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.